Filing Flows › CG Oncology (CGON) › Q3 2026 › vs Q2 2026
CG Oncology (CGON) Q3 2026 vs Q2 2026 (quarter over quarter)
CG Oncology's revenue rose $447K (+39%) from $1.2M in Q2 2026 to $1.6M in Q3 2026.
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6M | $1.2M | $447K | +39% |
| Other income, net | $6.4M | $7.3M | −$987K | -13% |
| Net loss | $56.9M | $79.1M | −$22.2M | -28% |
| Costs & expenses | $64.9M | $87.6M | −$22.7M | -26% |
| Operating costs | $64.9M | $87.6M | −$22.7M | -26% |
| Research & development | $39.2M | $54.7M | −$15.4M | -28% |
| General & admin | $23.0M | $29.0M | −$6.0M | -21% |
| Operating cash sources | $57.3M | $61.6M | −$4.3M | -7% |
| Depreciation & amortization | $1.2M | $850K | $305K | +36% |
| Share-based compensation | $8.5M | $14.3M | −$5.9M | -41% |
| Cash used in operations | $47.7M | $46.4M | $1.3M | +3% |
| Net loss absorbed | $56.9M | $79.1M | −$22.2M | -28% |
| Working capital & other | $427K | −$17.5M | $17.9M | — |
Questions
How much did CG Oncology's revenue grow quarter over quarter in Q3 2026?
CG Oncology's revenue rose $447K (+39%) from $1.2M in Q2 2026 to $1.6M in Q3 2026.